Maurice Brownlee, APRN
Psychiatric/Mental Health · Chicago, ILNPI 1083145262
Payments from drug & device makers
Across 1,124 payments — averaging $144.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$95K
- Viiv Healthcare Company$34K
- Theratechnologies Inc.$13K
- EMD Serono, Inc.$12K
- Napo Pharmaceuticals Inc$2K
- AbbVie$1K
- plus $6K from 32 others
What the payments were for
- Consulting fees$13,0309%
- Speaking & faculty fees$77,93651%
- Travel & lodging$36,10524%
- Food & beverage$23,33515%
- Education$9521%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 279 | $94,726 |
| Viiv Healthcare Company | 388 | $33,924 |
| Theratechnologies Inc. | 33 | $12,527 |
| EMD Serono, Inc. | 33 | $11,787 |
| Napo Pharmaceuticals Inc | 65 | $2,148 |
| AbbVie | 61 | $1,265 |
| Novo Nordisk | 68 | $1,029 |
| Merck | 31 | $804 |
| Johnson & Johnson(2 entities) | 31 | $698 |
| Lilly USA, LLC | 19 | $371 |
| Amgen | 21 | $328 |
| Novartis | 15 | $323 |
| Janssen Products, LP | 3 | $249 |
| Otsuka America Pharmaceutical, Inc. | 10 | $201 |
| Ardelyx, Inc. | 6 | $163 |
| Pfizer | 7 | $153 |
| Antares Pharma, Inc. | 6 | $139 |
| Echosens North America, Inc. | 1 | $125 |
| Corcept Therapeutics | 4 | $109 |
| Axsome Therapeutics, Inc. | 5 | $104 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $102 |
| Lundbeck LLC | 3 | $70 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $62 |
| Halozyme Inc | 4 | $61 |
| Abbott | 3 | $59 |
| Inspire Medical Systems, Inc. | 2 | $55 |
| Brainsway USA Inc | 1 | $53 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $52 |
| Currax Pharmaceuticals LLC | 3 | $50 |
| GSK | 2 | $39 |
| Idorsia Pharmaceuticals US Inc | 2 | $34 |
| Teva Pharmaceuticals USA, Inc. | 1 | $27 |
| Neurocrine Biosciences, Inc. | 1 | $26 |
| Vivus LLC | 1 | $22 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $21 |
| Corium, LLC | 1 | $20 |
| Exact Sciences | 1 | $15 |
| Medline Industries LP | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$161,958 in reported general payments places this provider in the 95th percentile of 922 psychiatric/mental health providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 167 | $726,536 |
| SerostimSomatropin | 22 | $537,901 |
| CabenuvaCabotegravir/Rilpivirine | 61 | $398,586 |
| MounjaroTirzepatide | 366 | $380,867 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 30 | $236,669 |
| OzempicSemaglutide | 132 | $123,169 |
| TivicayDolutegravir Sodium | 38 | $114,588 |
| DovatoDolutegravir Sodium/Lamivudine | 35 | $102,211 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 19 | $82,750 |
| DescovyEmtricitabine/Tenofov Alafenam | 35 | $78,431 |
| PrezcobixDarunavir/Cobicistat | 29 | $77,605 |
| Repatha SureclickEvolocumab | 128 | $72,276 |
| JulucaDolutegravir/Rilpivirine | 21 | $71,827 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 13 | $71,663 |
| WegovySemaglutide | 24 | $35,014 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy | $94,726 | $887,718221 claims |
| Viiv Healthcare CompanyCabenuva, Tivicay, Dovato, Juluca | $33,924 | $687,212155 claims |
| EMD Serono, Inc.Serostim | $11,787 | $537,90122 claims |
| Lilly USA, LLCMounjaro | $371 | $380,867366 claims |
| Novo NordiskOzempic, Wegovy, Rybelsus | $1,029 | $179,370183 claims |
| Johnson & JohnsonPrezcobix, Xarelto | $698 | $92,09151 claims |
| Janssen Products, LPSymtuza | $249 | $71,66313 claims |
| AbbVieLinzess, Ubrelvy, Lexapro | $1,265 | $38,76062 claims |
| MerckIsentress | $804 | $28,24012 claims |
| PfizerEliquis | $153 | $19,03322 claims |
| GSKTrelegy Ellipta | $39 | $16,92625 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $102 | $6,88013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 922 psychiatric/mental health providers in Illinois.
Other psychiatric/mental health in Chicago
- Erin PetrusicChicago$517K
- Melissa VitaleChicago$151K
- Alan AmbergChicago$119K
- Julie CarbrayChicago$36K
- Abigail HamiltonChicago$14K
- Anh NguyenChicago$9K
- Sherann IvyChicago$8K
- Annabella Vidal-RuizChicago$8K
- Dina Pierre-GrayChicago$7K
- Natalia RysmanowskaChicago$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.